Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158632654> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2158632654 endingPage "374" @default.
- W2158632654 startingPage "369" @default.
- W2158632654 abstract "Data from studies in diabetic rodents and evidence from clinical situations of severe resistance to insulin suggest that insulin-like growth factor I (IGF-I) is able to at least partly overcome insulin resistance. To assess the efficacy of recombinant human IGF-I in subjects with the most common form of insulin resistance, e.g., obese, type II diabetic patients, we administered recombinant human IGF-I (rhIGF) in doses of 120 and 160 micrograms/kg twice daily for 4-52 days to seven such individuals who had been treated previously with high doses of insulin (> 0.7 U.kg-1 x day-1). Four patients exhibited comparable or enhanced, whereas three had diminished, blood glucose control on rhIGF-I relative to that while on twice daily NPH insulin during the six-week control period. The occurrence of adverse effects in all patients compelled us to discontinue rhIGF-I administration before completing the 8-week treatment period. These adverse effects included edema primarily on the face and hands, mild weight gain, occasional dyspnea, bilateral jaw tenderness, arthralgias and myalgias, fatigue, tachycardia, flushing, orthostatic hypotension, and local burning at the injection site. We conclude that the frequency and severity of side effects associated with administering high-dose subcutaneous rhIGF-I to obese insulin-resistant diabetic patients make it an unacceptable therapeutic agent for these patients despite its ability to produce reasonable blood glucose control in approximately 50% of them." @default.
- W2158632654 created "2016-06-24" @default.
- W2158632654 creator A5021016538 @default.
- W2158632654 creator A5027066916 @default.
- W2158632654 creator A5033742663 @default.
- W2158632654 creator A5036725028 @default.
- W2158632654 creator A5039702476 @default.
- W2158632654 creator A5050281766 @default.
- W2158632654 creator A5054183066 @default.
- W2158632654 creator A5064307950 @default.
- W2158632654 creator A5076739489 @default.
- W2158632654 date "1994-03-01" @default.
- W2158632654 modified "2023-10-15" @default.
- W2158632654 title "Adverse Effects of Recombinant Human Insulin-like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients" @default.
- W2158632654 doi "https://doi.org/10.2337/diab.43.3.369" @default.
- W2158632654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8314009" @default.
- W2158632654 hasPublicationYear "1994" @default.
- W2158632654 type Work @default.
- W2158632654 sameAs 2158632654 @default.
- W2158632654 citedByCount "92" @default.
- W2158632654 countsByYear W21586326542012 @default.
- W2158632654 countsByYear W21586326542013 @default.
- W2158632654 countsByYear W21586326542015 @default.
- W2158632654 countsByYear W21586326542016 @default.
- W2158632654 countsByYear W21586326542017 @default.
- W2158632654 countsByYear W21586326542018 @default.
- W2158632654 countsByYear W21586326542021 @default.
- W2158632654 crossrefType "journal-article" @default.
- W2158632654 hasAuthorship W2158632654A5021016538 @default.
- W2158632654 hasAuthorship W2158632654A5027066916 @default.
- W2158632654 hasAuthorship W2158632654A5033742663 @default.
- W2158632654 hasAuthorship W2158632654A5036725028 @default.
- W2158632654 hasAuthorship W2158632654A5039702476 @default.
- W2158632654 hasAuthorship W2158632654A5050281766 @default.
- W2158632654 hasAuthorship W2158632654A5054183066 @default.
- W2158632654 hasAuthorship W2158632654A5064307950 @default.
- W2158632654 hasAuthorship W2158632654A5076739489 @default.
- W2158632654 hasConcept C126322002 @default.
- W2158632654 hasConcept C134018914 @default.
- W2158632654 hasConcept C197934379 @default.
- W2158632654 hasConcept C2777391703 @default.
- W2158632654 hasConcept C2779306644 @default.
- W2158632654 hasConcept C2780668416 @default.
- W2158632654 hasConcept C555293320 @default.
- W2158632654 hasConcept C71924100 @default.
- W2158632654 hasConcept C73787029 @default.
- W2158632654 hasConcept C84393581 @default.
- W2158632654 hasConceptScore W2158632654C126322002 @default.
- W2158632654 hasConceptScore W2158632654C134018914 @default.
- W2158632654 hasConceptScore W2158632654C197934379 @default.
- W2158632654 hasConceptScore W2158632654C2777391703 @default.
- W2158632654 hasConceptScore W2158632654C2779306644 @default.
- W2158632654 hasConceptScore W2158632654C2780668416 @default.
- W2158632654 hasConceptScore W2158632654C555293320 @default.
- W2158632654 hasConceptScore W2158632654C71924100 @default.
- W2158632654 hasConceptScore W2158632654C73787029 @default.
- W2158632654 hasConceptScore W2158632654C84393581 @default.
- W2158632654 hasIssue "3" @default.
- W2158632654 hasLocation W21586326541 @default.
- W2158632654 hasLocation W21586326542 @default.
- W2158632654 hasOpenAccess W2158632654 @default.
- W2158632654 hasPrimaryLocation W21586326541 @default.
- W2158632654 hasRelatedWork W1967030430 @default.
- W2158632654 hasRelatedWork W1975376060 @default.
- W2158632654 hasRelatedWork W1981090134 @default.
- W2158632654 hasRelatedWork W2086370867 @default.
- W2158632654 hasRelatedWork W2127515233 @default.
- W2158632654 hasRelatedWork W2257547052 @default.
- W2158632654 hasRelatedWork W2482177913 @default.
- W2158632654 hasRelatedWork W2884512083 @default.
- W2158632654 hasRelatedWork W3029801470 @default.
- W2158632654 hasRelatedWork W4281261440 @default.
- W2158632654 hasVolume "43" @default.
- W2158632654 isParatext "false" @default.
- W2158632654 isRetracted "false" @default.
- W2158632654 magId "2158632654" @default.
- W2158632654 workType "article" @default.